Liprotide cytotoxicity was not limited to the MCF7 breast carcinoma cell line (positive estrogen (ER+) and progesterone (PR+) receptor and negative human epidermal growth factor (HER2-) receptors); both liprotides kill MDA-MB-231 (triple negative breast cancer cells; ER-/PR-/HER2-) and HeLa cells (human cervical epithelia adenocarcinoma) with efficiency comparable to that against MCF7 cells (Supplementary Fig. S1). The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.